Alexander Stevenson
Gründer bei 4D PHARMA PLC
Vermögen: 73 092 $ am 30.04.2024
Aktive Positionen von Alexander Stevenson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| 4D PHARMA PLC | Direktor/Vorstandsmitglied | 18.02.2014 | - |
| Technik-/Wissenschafts-/F&E-Leiter | 18.02.2014 | - | |
| Gründer | 18.02.2014 | - | |
| C4X DISCOVERY HOLDINGS PLC | Direktor/Vorstandsmitglied | 03.09.2014 | - |
Aquarius Equity Partners Ltd.
 Aquarius Equity Partners Ltd. Investment ManagersFinance Aquarius Equity Partners Ltd is an independent private equity firm founded in the year 2002 by Alan John Aubrey and Duncan Joseph Peyton headquarters in the UK. | Private Equity Investor | 01.01.2008 | - |
| Aquarius IV Fund Managing Member Ltd. | Direktor/Vorstandsmitglied | - | - |
C4X Discovery Ltd.
 C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Direktor/Vorstandsmitglied | - | - |
| Schosween 18 Ltd. | Direktor/Vorstandsmitglied | - | - |
The Microbiota Co. Ltd.
 The Microbiota Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of 4D Pharma Plc, The Microbiota Co. Ltd. develops a patented bacteria which treats irritable bowel syndrome and related symptoms. The private company is based in Manchester, UK. The Microbiota Co. was acquired by 4D Pharma Plc on July 18, 2014 for $1.65 million. | Direktor/Vorstandsmitglied | - | - |
| North West Seed Fund General Partner Ltd. | Direktor/Vorstandsmitglied | - | - |
| Aquarius Life Science Ltd. | Direktor/Vorstandsmitglied | - | - |
| ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░ ░░░░░░ ░░░░ ░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Karriereverlauf von Alexander Stevenson
Ehemalige bekannte Positionen von Alexander Stevenson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ░░░░░░ ░░░░░░░ ░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░ ░░░░░ ░░░ | ░░░░░░░░░ | - | - |
Ausbildung von Alexander Stevenson
| University of Leeds | Doctorate Degree |
Statistik
International
| Vereinigtes Königreich | 20 |
Operativ
| Director/Board Member | 15 |
| Founder | 2 |
| Private Equity Investor | 1 |
Sektoral
| Health Technology | 9 |
| Finance | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| TISSUE REGENIX GROUP PLC | Health Technology |
| AVACTA GROUP PLC | Commercial Services |
| 4D PHARMA PLC | Health Technology |
| C4X DISCOVERY HOLDINGS PLC | Health Technology |
| Private Unternehmen | 14 |
|---|---|
Aquarius Equity Partners Ltd.
Aquarius Equity Partners Ltd. Investment ManagersFinance Aquarius Equity Partners Ltd is an independent private equity firm founded in the year 2002 by Alan John Aubrey and Duncan Joseph Peyton headquarters in the UK. | Finance |
Modern Biosciences Ltd.
 Modern Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Part of Istesso Ltd., Modern Biosciences Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The private company is based in London, UK. The company was founded by Samuel Cameron Williams, Alexander James Stevenson. Samuel Cameron Williams has been the CEO since incorporation. | Health Technology |
GT Biologics Ltd.
 GT Biologics Ltd. Pharmaceuticals: MajorHealth Technology GT Biologics Ltd. manufactures and distributes pharmaceutical products. It develops and commercializes an oral-based probiotic product for the treatment of mild to moderate Crohn's disease and ulcerative colitis and a novel family of protein, peptide therapeutics for the treatment of moderate to severe inflammatory bowel diseases. The company was founded by Denise Kelly in 2008 and is headquartered in Leeds, the United Kingdom. | Health Technology |
Aquarius Equity Holdings Ltd.
 Aquarius Equity Holdings Ltd. Financial ConglomeratesFinance Aquarius Equity Holdings Ltd. functions as an investment holding British company. The private company is based in Manchester, UK. and has subsidiaries in United Kingdom. | Finance |
| Aquarius Equity Director Ltd. | |
| Aquarius Origin Fund Managing Member Ltd. | |
| Aquarius IV Fund Managing Member Ltd. | |
| Aquarius Northern Entrepreneurs Managing Member Ltd. | |
| Aquarius Life Science Ltd. | |
| North West Seed Fund General Partner Ltd. | |
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
The Microbiota Co. Ltd.
The Microbiota Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of 4D Pharma Plc, The Microbiota Co. Ltd. develops a patented bacteria which treats irritable bowel syndrome and related symptoms. The private company is based in Manchester, UK. The Microbiota Co. was acquired by 4D Pharma Plc on July 18, 2014 for $1.65 million. | Health Technology |
| Schosween 18 Ltd. | |
C4X Discovery Ltd.
C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Alexander Stevenson
- Erfahrung
